



Media release

CVS Health expands the use of SHL Telemedicine SmartHeart™ full 12 lead ECG technology

CVS Health Clinical Trial Services™ will use SmartHeart™ 12 Lead ECG in clinical trials

Tel Aviv / Zurich – March 21, 2022 – SHL Telemedicine Ltd. today announced that CVS Health Clinical Trial Services™ will use SHL's SmartHeart™ technology for delivery of full 12 Lead ECGs in clinical trials, to effectively deliver clinical trials in a way that improves patient access, engagement and retention to advance research effectiveness.

CVS Health Clinical Trial Services™ is working with key stakeholders in the biopharmaceutical industry and across the clinical trial ecosystem to design and deliver innovative approaches to research and real-world evidence generation.

"We are proud to collaborate with CVS Health Clinical Trial Services™ that provides innovative, decentralized options for the delivery of Phase III/IV clinical trials and real-world evidence studies at CVS locations, at home or virtually," said Erez Nachtom, CEO of SHL Telemedicine. "We developed and enhanced our unique SmartHeart™ platform to add new capabilities for use in delivery of clinical research, and this is a new dimension and another meaningful step up for SHL's activity in the US, as we continue to pursue and implement our strategy for fast growth in the US market."

Further information

Elisabeth Wallimann, IRF, Phone: +41 43 244 81 41, shl@irf-reputation.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit our web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.